source
- UCB stock slides despite Bimzelx revenue beating forecastsUCB shares dropped Thursday on investor concern that the Belgian pharma could be overpromising on its full-year forecast, even as sales of its lead drug topped analysts' expectations. The company r…Endpoints · 3h ago↗ source
- Garijo's plan to revamp Sanofi: an R&D cleanup, more M&A and a China pushThree months into her role as CEO at Sanofi, Belén Garijo gave some insight on how she plans to boost the French company’s mid- to long-term growth in the face of a looming patent cliff ...Endpoints · 3h ago↗ source
- Pfizer's Phase 3 win for Litfulo; Braveheart, Attovia eye IPOs of $275M, $182MPfizer reports Phase 3 wins for Litfulo: The drug succeeded in two trials for active and stable nonsegmental vitiligo, an autoimmune condition that causes skin to progressively lose its color. One ...